Status:
COMPLETED
The 90% Effective Flow of High Flow Nasal Oxygenation (HFNO) During Sedated Bronchoscopy
Lead Sponsor:
Zhejiang Cancer Hospital
Conditions:
Hypoxia
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Patients undergoing sedated bronchoscopy were randomized into six groups (10 Liters/minute \[L/min\], 20 L/min, 30 L/min, 40 L/min, 50 L/min, 60 L/min). The primary outcome was the incidence of hypoxe...
Detailed Description
It's a double-blind, randomized trial. The patients'demographic information, such as sex, weight, height, smoking status, present illness and history of past illness, were collected. After successful ...
Eligibility Criteria
Inclusion
- (1) undergoing sedated bronchoscopy
- (2) 18 to 70 years of age;
- (3) American Society of Anaesthesiologists (ASA) class: I-III
Exclusion
- (1) severe cardiac disease, including aortic stenosis, mitral stenosis, hemodynamic instability caused by severe arrhythmia, and acute myocardial infarction or cardiac surgery within the last 6 months;
- (2) severe hypoxemia (SpO2 \< 90% without oxygen supply on admission), caused by interstitial lung disease, end-stage chronic obstructive pulmonary disease (COPD) or other diseases;
- (3) upper respiratory tract infection or lung infection;
- (4) refusal to participate in this study.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2022
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT05298319
Start Date
April 1 2022
End Date
August 31 2022
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022